Patents by Inventor Kenneth E. Palmer
Kenneth E. Palmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365633Abstract: The invention is directed to methods of treating or preventing a Rhabdoviridae virus infection in a mammal comprising administering griffithsin, or a fragment or mutant thereof, to the mammal.Type: ApplicationFiled: October 9, 2020Publication date: November 16, 2023Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc.Inventors: Nadia F. Gallardo-Romero, Barry R. O'Keefe, Kenneth E. Palmer
-
Publication number: 20230218715Abstract: The present invention relates to griffithsin polypeptides and methods of using the same in inhibition of viral infection. Certain embodiments of the present invention relate to modified griffithsin polypeptides and methods of inhibiting coronavirus infection in a host by administering modified griffithsin polypeptides to the upper respiratory tract of the host. Further embodiments relate to an intranasal spray formulation including griffithsin polypeptides in a composition including a preservative and a viscosity modifier.Type: ApplicationFiled: May 18, 2021Publication date: July 13, 2023Inventors: Kenneth E. Palmer, Joshua L. Fuqua, Lisa Cencia Rohan, Lin Wang, Barry R. O'Keefe
-
Publication number: 20220315629Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: ApplicationFiled: April 19, 2022Publication date: October 6, 2022Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Publication number: 20220289798Abstract: Provided herein are GRFT variants and methods of using such GRFT variants. The GRFT variants described herein can be PEGylated, which significantly improves the pharmacokinetics and decreases the immunogenicity of the GFRT composition.Type: ApplicationFiled: September 10, 2020Publication date: September 15, 2022Applicants: University of Louisville Research Foundation, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Joshua Fuqua, Krystal Hamorsky, Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer
-
Patent number: 11339195Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: GrantFiled: November 27, 2019Date of Patent: May 24, 2022Inventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Publication number: 20210299156Abstract: A method of administering an anti-nucleolin agent to a patient by delivering the anti-nucleolin agent to the mouth, lungs, throat, nose and eyes of a patient to prevent COVID-19. Compositions for administering an anti-nucleolin agent comprising a container and a formulation including an anti-nucleolin agent. The anti-nucleolin agent may be administered via an inhaler, nasal spray or eye drop.Type: ApplicationFiled: March 29, 2021Publication date: September 30, 2021Applicant: Qualigen Inc.Inventors: Paula J. Bates, Kenneth E. Palmer, Wajdi Abdul-Ahad, Michael Poirier
-
Publication number: 20200087359Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: ApplicationFiled: November 27, 2019Publication date: March 19, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Patent number: 10501507Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: GrantFiled: February 10, 2016Date of Patent: December 10, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Louisville Research Foundation, Inc., University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Publication number: 20180016307Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: ApplicationFiled: February 10, 2016Publication date: January 18, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Publication number: 20160175426Abstract: Polypeptides, compositions, and methods for treatment of papillomavirus (PV) infections including a papillomavirus (PV) minor capsid (L2) polypeptide fragment and a cholera toxin B subunit (CTB) polypeptide are described. Polypeptides and compositions disclosed herein can be administered to the mucosa of a subject, resulting in unexpectedly beneficial production of cross-neutralizing antibodies.Type: ApplicationFiled: July 16, 2014Publication date: June 23, 2016Inventors: Kenneth E. Palmer, Nobuyuki Matoba, Joshua Fuqua
-
Patent number: 7939318Abstract: Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.Type: GrantFiled: April 24, 2006Date of Patent: May 10, 2011Assignee: Kentucky Bioprocessing, LLCInventors: Alison A. McCormick, Mark L. Smith, Kenneth E. Palmer, John A. Lindbo, Long V. Nguyen, Gregory P. Pogue
-
Publication number: 20090208522Abstract: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.Type: ApplicationFiled: August 22, 2008Publication date: August 20, 2009Inventors: David E. Junker, Mark D. Cochran, Mark L. Smith, Kenneth E. Palmer, Gregory P. Pogue
-
Publication number: 20090053261Abstract: Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the “free” protein antigen. The 2100 coat proteins comprising the rod-shaped capsid of Tobacco mosaic virus (TMV) can accommodate short peptide insertions into the primary sequence, but the display of larger protein moieties on the virion surface by genetic fusions to the capsid protein has not been possible. Since TMV lacks surface exposed residues compatible with commonly available linker chemistries, we employed a randomized library approach to introduce a reactive lysine at the externally located at the amino-terminus of the coat protein. We found that we could easily control the extent of virion conjugation and demonstrated stoichiometric biotinylation of the introduced lysine.Type: ApplicationFiled: September 8, 2006Publication date: February 26, 2009Inventors: John A. Lindbo, Kenneth E. Palmer, Mark L. Smith
-
Patent number: 7432079Abstract: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.Type: GrantFiled: December 21, 2005Date of Patent: October 7, 2008Assignee: Schering-Plough Animal Health CorporationInventors: David E. Junker, Mark D. Cochran, Mark L. Smith, Kenneth E. Palmer, Gregory P. Pogue
-
Publication number: 20080213293Abstract: Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes.Type: ApplicationFiled: December 4, 2007Publication date: September 4, 2008Applicant: LARGE SCALE BIOLOGY CORPORATIONInventors: Kenneth E. Palmer, Daniel Tuse, Stephen J. Reinl, Mark L. Smith, Gregory P. Pogue
-
Patent number: 7049134Abstract: A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral taxonomic families Geminiviridae, Circoviridae or genus Nanovirus. The Rep gene open reading frame is placed under transcriptional control of a promoter, which is placed 5? of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon are included. An expression cassette for expression of an ancillary protein that is capable of creating a cellular environment permissive for replication of the rolling circle DNA replicon in the host cell of interest is also included.Type: GrantFiled: November 1, 2002Date of Patent: May 23, 2006Assignee: Large Scale Biology CorporationInventors: Kenneth E. Palmer, Gregory P. Pogue
-
Publication number: 20040253687Abstract: A plurality of proteins of interest, or peptides of interest, or other genetically expressed materials, are screened and subsequently produced using any of a variety of expression systems. The plurality of proteins are extracted from a plurality of separate, processed green juices, each green juice containing one of the proteins of interest. A multi-channel apparatus processes the various green juices, one green juice per channel. The apparatus is computer controlled such that the various valves in each channel and pump are controlled in an automated manner to extract each protein of interest and deliver each protein of interest into its own storage vessel.Type: ApplicationFiled: June 29, 2004Publication date: December 16, 2004Inventors: Mark L. Smith, Kenneth E. Palmer, Gregory P. Pogue, John A. Lindbo, Kathleen M. Hanley, David P. Mannion, Gershon M. Wolfe
-
Publication number: 20040170606Abstract: Vaccines and diagnostic composition are made and used for preventing, treating and detecting antigens from a papilloma virus, ebola virus, HIV virus, Rift Valley Fever virus or a parvovirus. The epitopes of these viruses are produced as genetically engineered fusion peptides in plants by infection with a recombinant tobamovirus vectors to express fusion proteins containing the epitope peptides.Type: ApplicationFiled: September 3, 2003Publication date: September 2, 2004Inventors: Kenneth E. Palmer, Long V. Nguyen, Rachel L. Toth, Michael Jones, Sean Chapman, Lisa Smolenska, Alison A. McCormick, Gregory P. Pogue
-
Publication number: 20040033585Abstract: Herein described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.Type: ApplicationFiled: June 6, 2003Publication date: February 19, 2004Inventors: Alison A. McCormick, Mark L. Smith, Kenneth E. Palmer, John A. Lindbo, Long V. Nguyen, Gregory P. Pogue
-
Publication number: 20030143741Abstract: A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral taxonomic families Geminiviridae, Circoviridae or genus Nanovirus. The Rep gene open reading frame is placed under transcriptional control of a promoter, which is placed 5′ of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon are included. An expression cassette for expression of an ancillary protein that is capable of creating a cellular environment permissive for replication of the rolling circle DNA replicon in the host cell of interest is also included.Type: ApplicationFiled: November 1, 2002Publication date: July 31, 2003Applicant: Large Scale Biology CorporationInventors: Kenneth E. Palmer, Gregory P. Pogue